Evolving CLL treatments: creating choices and igniting discussions
Deborah Henderson et al.
Is double autologous transplantation in multiple myeloma superior in the age of new agents?
Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?
SWOG S0777 trial: lenalidomide, dexamethasone and bortezomib for the treatment of MM
Why MRD is a hot topic in CLL and how it should be used